Skip to main content

Table 1 Baseline data of LUAD patients according to the expression and proportion of the K-Ras4A isoform

From: Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients

Clinical parameters Values All patients K-Ras4A expressiona K-Ras4A proportionb
N (%) High [N (%)] Low [N (%)] p-valuec High [N (%)] Low [N (%)] p-value
Age ≥65 276 (53.5) 137 (26.6) 139 (26.9) 1.0 141 (27.3) 135 (26.2) 0.616
< 65 221 (42.8) 110 (21.3) 111 (21.5)   107 (20.7) 114 (22.1)  
NAd 19 (3.7) 11 (2.1) 8 (1.6)   10 (1.9) 9 (1.9)  
Gender Male 238 (46.1) 119 (23.1) 119 (23.1) 1.0 117 (22.7) 121 (23.4) 0.791
Female 278 (53.9) 139 (26.9) 139 (26.9)   141 (27.3) 137 (26.6)  
Smoking history Yes 427 (82.8) 219 (42.4) 208 (40.3) 0.299 215 (41.7) 212 (41.1) 1.0
No 75 (14.5) 33 (6.4) 42 (8.1)   38 (7.4) 37 (7.2)  
NA 14 (2.7) 6 (1.2) 8 (1.6)   5 (1.0) 9 (1.7)  
KRAS amplificatione Present 61 (11.8) 42 (8.1) 19 (3.7) 2.70E-3 30 (5.8) 31 (6.0) 1.0
Absent 455 (88.2) 216 (41.9) 239 (46.3)   228 (44.2) 227 (44.0)  
KRAS mutations Present 148 (28.7) 110 (21.3) 38 (7.4) 4.82E-12 101 (19.6) 47 (9.1) 2.49E-7
Absent 368 (71.3) 148 (28.7) 220 (42.6)   157 (30.4) 211 (40.9)  
EGFR mutations Present 45 (8.7) 12 (2.3) 33 (6.4) 1.81E-3 14 (2.7) 31 (6.0) 0.0125
Absent 471 (91.3) 246 (47.7) 225 (43.6)   244 (47.3) 227 (44.0)  
Pathological stage I 276 (53.5) 125 (24.2) 151 (29.3) 0.0460 128 (24.8) 148 (28.7) 0.0327
II 122 (23.6) 66 (12.8) 56 (10.9)   58 (11.2) 64 (12.4)  
III 84 (16.3) 52 (10.1) 32 (6.2)   54 (10.5) 30 (5.8)  
IV 26 (5.0) 13 (2.5) 13 (2.5)   14 (2.7) 12 (2.3)  
NA 8 (1.6) 2 (0.4) 6 (1.2)   4 (0.8) 4 (0.8)  
  1. aMedian value (3.41 TPM) of K-Ras4A expression levels was used to divide LUAD patients into two groups
  2. bMedian value (0.1659) of K-Ras4A proportions was used to divide LUAD patients into two groups
  3. cChi square tests were used to examine the relationship between the nominal variables
  4. dNA, Not available
  5. eThe presence or absence of KRAS amplification were defined to 10% or more KRAS amplified or not